The study reveals how FGF21 acts in the brain, alters metabolism, and paves the way for new strategies against obesity and liver diseases
A recent scientific discovery has drawn attention by indicating a new path in the treatment of obesity, reorganizing the understanding of metabolism and expanding therapeutic possibilities. Researchers from the University of Oklahoma identified, in 2026, that the natural hormone FGF21 can reverse obesity in animal models, thereby evidencing a new mechanism of energy regulation. The study was published in the scientific journal Cell Reports and has gained relevance in the academic community, although it still requires validation in humans.
Scientific review reveals new action of FGF21 in the brain
For years, FGF21 was mainly associated with the liver, which limited the understanding of its action in the body. The new analysis, however, demonstrates that the hormone acts directly in the brainstem, a region responsible for vital functions and also for the control of metabolism. This finding alters the previous theoretical basis and broadens the understanding of how the body regulates energy, especially since FGF21 interacts with the nucleus of the solitary tract and the area postrema. These structures connect to other regions involved in energy regulation, highlighting a more complex circuit than previously imagined.
Difference in mechanism compared to current medications
The most well-known medications for the treatment of obesity, such as Ozempic and Wegovy, primarily work by reducing appetite, leading to lower food intake throughout the day. FGF21, on the other hand, follows a different path, as it does not directly interfere with hunger. Instead, the hormone increases the body’s energy expenditure, causing the body to burn more calories and consequently favoring weight loss. This mechanism represents an important shift in the therapeutic approach, as it expands the possibilities for intervention in metabolism.
-
China consolidates high-precision mapping and identifies vast mineral wealth in the eastern seabed to boost the technology industry.
-
Scientists discover unexpected climate benefit hidden in forest soils related to atmospheric methane absorption.
-
Sandy unproductive land can become a highly profitable area with a simple technique that boosts soybeans and corn to over 100 sacks.
-
The new Kia hatch will have a range of up to 480 km, may cost up to 25,000 euros (around R$ 150,000), and promises to become one of the most affordable electric cars in Europe; meet the Kia Picanto Electric.
Metabolic impact and expanded therapeutic potential
In addition to obesity, FGF21 is also being investigated in other metabolic conditions, such as MASH, a severe form of fatty liver disease. This direction indicates that the hormone may have broader applications within medicine. Experimental therapies based on FGF21 are already under development and are being tested in clinical trials, demonstrating the growing interest of the scientific community. Researchers hope that by better understanding this brain circuit, it will be possible to develop more effective treatments for both obesity and liver diseases.
Limitations of the study and the need for validation in humans
Despite the results being considered relevant, the tests were conducted in animal models, which prevents direct application in humans at this time. New studies will be necessary to evaluate the safety and efficacy of FGF21 in people, an essential step for any clinical advancement. Nevertheless, the study represents an important step in understanding metabolic mechanisms and reinforces the potential of the hormone as a therapeutic target.
Scientific advancement repositions strategies against obesity
The discovery of FGF21’s action in the brain reorganizes the way metabolism can be treated, while also expanding the possibilities for the development of new therapies. This advancement contributes to a more comprehensive view of the body’s energy control and reinforces the importance of scientific research in tackling complex diseases.
In light of this scenario, could FGF21 redefine, in the future, the strategies used in the fight against obesity and metabolic diseases?

Seja o primeiro a reagir!